The RADxx 2020 Awardees share their hopes and insights from what the future of medical imaging informatics might look like.
Radiology is known to be a specialty of innovation – and its arm of medical imaging informatics falls right in line with that description. It is also segment of radiology that has dedicated significant levels of energy to growing its cadre of female providers. Each year, RADxx, an initiative spear-headed by Dr. Geraldine McGinty and Ambra Health that fosters networking and mentoring opportunities for women in radiology, selects four people throughout the industry to highlight the contributions they have made to imaging informatics.
This year, they selected Dr. Cheryl Petersilge, CEO and founder of consulting company Vidagos, as their RADxx Trailblazer, Dr. Carol Wu, a cardiothoracic radiologist, as the RADxx Rising Star, Dr. Ann Scherzinger, a radiology professor from the University of Colorado, as the RADxx Champion, and Dr. Alexander Towbin, chair of radiology informatics at Cincinnati Children’s Hospital, as the RADxx Advocate.
Diagnostic Imaging spoke with each awardee about what they envision for the future of medical imaging informatics – not only in relation to the growing number of women in the field, but for the sub-specialty overall. Here are their insights.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.